Exploring the effect of transient exposure on the risk of acute events by means of time-window designs: An application to fluoroquinolone antibacterials and arrhythmia

Pharmacoepidemiology and Drug Safety

Volumn 15, Issue 1, 2006, Pages 31-37

  Corrao, Giovanni ^a   Botteri, Edoardo ^a   Bertù, Lorenza ^a   Zambon, Antonella ^a   Favilli, Sergio ^b  

^a UNIVERSITY OF MILANO BICOCCA   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Arrhythmia; Automated databases; Cohort; Fluoroquinolone antibacterials; Pharmacoepidemiology; Time window design

Indexed keywords

ANTIARRHYTHMIC AGENT; CIPROFLOXACIN; ENOXACIN; LEVOFLOXACIN; LOMEFLOXACIN; NORFLOXACIN; OFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RUFLOXACIN;

ADULT; AGED; ARTICLE; COHORT ANALYSIS; CONFIDENCE INTERVAL; CONTROLLED STUDY; DRUG EXPOSURE; FEMALE; FOLLOW UP; HEART ARRHYTHMIA; HIGH RISK POPULATION; HOSPITALIZATION; HUMAN; INCIDENCE; INFECTION; ITALY; MAJOR CLINICAL STUDY; MALE; POPULATION RESEARCH; PRESCRIPTION; PRIORITY JOURNAL; RISK ASSESSMENT;

ANTI-BACTERIAL AGENTS; ARRHYTHMIA; COHORT STUDIES; EPIDEMIOLOGIC RESEARCH DESIGN; FLUOROQUINOLONES; HOSPITALIZATION; HUMANS; INCIDENCE; TIME FACTORS;

EID: 31744442887     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.1125     Document Type: Article

References (24)

1. Suissa S. Novel approaches to pharmacoepidemiology study design and statistical analysis. In Pharmacoepidemiology, Strom BL (ed.). John Wiley & Sons: New York, 2000; 785-805.
2. McMahon AD, Evans JMM, McGilchrist MM, McDevitt DG, MacDonald TM. Drug exposure risk windows and unexposed comparator groups for cohort studies in pharmacoepidemiology. Pharmacoepidemiol Drug Safe 1998; 7: 275-280.
3. Miettinen OS, Caro JJ. Principles of nonexperimental assessment of excess risk, with special reference to adverse drug reactions. J Clin Epidemiol 1989; 42: 325-331.
4. Jick H. Use of automated data bases to study drug effects after marketing. Pharmacotherapy 1985; 5: 278-279.
5. Ray WA, Griffin MR. Use of MEDICAID data for pharmacoepidemiology. Am J Epidemiol 1989; 129: 837-849.
6. Bright RA, Avorn J, Everitt DE. MEDICAID data as a resource for epidemiologic studies: strengths and limitations. J Clin Epidemiol 1989; 42: 937-945.
7. Crombie IK. The role of record linkage in postmarketing surveillance. Brit J Clin Pharmacol 1986; 22: 77s-82s.
8. Shapiro S. The role of automated record linkage in the post-marketing surveillance of drug safety: a critique. Clin Pharmacol Ther 1989; 46: 371-386.
9. Hallas J. Evidence of depression provoked by cardiovascular medication. A prescription sequence symmetry analysis. Epidemiology 1996; 7: 478-484.
10. Walker AM. Confounding by indication. Epidemiology 1996; 7: 335-336.
11. Bertino J, Fish D. The safety of the fluoroquinolones. Clin Ther 2000; 22: 798-817.
12. Frothingham R. Rates of torsades de pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin. Pharmacotherapy 2001; 21: 1468-1472.
13. + channel HERG. Mol Pharmacol 2001; 59: 122-126.
14. De Ponti F, Poluzzi E, Cavalli A, Recanatini M, Montanaro N. Safety of non-arrhythmic drugs that prolong the QT interval or induce torsade de pointes. Drug Saf 2002; 25: 263-286.
15. Owens RC Jr, Ambrose PG. Torsades de Pointes associated with fluoroquinolones. Pharmacotherapy 2002; 22: 663-668.
16. Clark DW, Layton D, Wilton LV, Pearce GL, Shakir SAW. Profiles of hepatic and dysrhythmic cardiovascular events following use of fluoroquinolone antibacterials. Drug Saf 2001; 24: 1143-1154.
17. WHO Collaborating Center for Drug Statistics Methodology. ATC Classification Index Including Defined Doses for Plan Substances. Oslo, WHO, 1995.
18. Breslow NE, Day NE. Statistical Methods in Cancer Research, Vol. II: The Design and Analysis of Cohort Studies. International Agency for Research on Cancer: Lyon, France, 1987.
19. Hastie T, Tibshirani R. Generalized Additive Models. Chapman & Hall: London, 1990.
20. Faich GA, Stadel BV. The future of automated record linkage for postmarketing surveillance: a response to Shapiro. Clin Pharmacol Ther 1989: 46: 387-389.
21. Van Staa TP, Abenhaim L, Leufkens HA. A study of the effects of exposure misclassification due to the time-window design in pharmacoepidemiologic studies. J Clin Epidemiol 1994; 47: 183-189.
22. Van Staa TP, Abenhaim L. Utilization dynamics and risk comparisons in studies that use prescription information. Pharmacoepidemiol Drug Safe 1994; 3: 191-197.
23. Leufkens HG, Urquhart J. Variability in patterns of drug usage. J Pharm Pharmacol 1994; 46: 433-437.
24. Maclure M. The case-crossover study design: a method for studying transient effects on the risk of acute events. Am J Epidemiol 1991; 133: 144-153.